David Laharie
A5009680823- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Diverticular Disease and Complications
- Helicobacter pylori-related gastroenterology studies
- Chronic Lymphocytic Leukemia Research
- Diagnosis and treatment of tuberculosis
- Liver Diseases and Immunity
- Celiac Disease Research and Management
- Gastric Cancer Management and Outcomes
- Pregnancy and Medication Impact
- Gastrointestinal disorders and treatments
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Gastrointestinal Tumor Research and Treatment
- Acute Lymphoblastic Leukemia research
- Tuberculosis Research and Epidemiology
- Liver Disease Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Mycobacterium research and diagnosis
- Anorectal Disease Treatments and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatitis Pathology and Treatment
Hôpital Cardiologique du Haut-Lévêque
2016-2025
Inserm
2009-2025
Université de Bordeaux
2016-2025
Centre Hospitalier Universitaire de Bordeaux
2016-2025
Bordeaux Population Health
2014-2025
Hôpital Saint Eloi
2025
Université de Montpellier
2025
Clinical Investigation Center Plurithematic Tours
2020-2024
University of Chicago
2023
Institut de Biologie et de Chimie des Protéines
2005-2022
Early endoscopic recurrence is frequent after intestinal resection for Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to the flora. Here we tested probiotic strain Lactobacillus johnsonii LA1 in this setting.This was a randomised, double blind, placebo controlled study. Patients were eligible if they had undergone surgical of <1 m, removing all macroscopic lesions within past 21 days. randomised receive two packets per day lyophilised (2 x 10(9) cfu) or...
Liver stiffness measurement using FibroScan is a novel rapid and non-invasive technique that evaluates liver fibrosis. In some cases, however, no elasticity obtained. The aim of this prospective study was to assess the prevalence factors associated with failure (no value obtained after 10 measurements) in patients chronic disease. Two thousand one hundred fourteen measurements were analyzed. Failure observed 96 cases (4.5%). not operator, gender, or transaminase level. By multivariate...
Background & AimsMost patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after We performed a randomized trial to compare the ability of infliximab vs placebo prevent recurrence.MethodsWe evaluated efficacy in preventing postoperative recurrence 297 at 104 sites worldwide from November 2010 through May 2012. All study had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) groups...
The efficacy of anti-tumour necrosis factors (anti-TNFs) in patients with Crohn's disease (CD) and symptomatic small bowel stricture (SSBS) is controversial. aim this study was to estimate the adalimumab these identify predicting success.We performed a multicentre, prospective, observational cohort CD SSBS. included underwent magnetic resonance enterography at baseline subsequently received adalimumab. primary endpoint success week 24, defined as continuation without prohibited treatment...
Crohn's disease (CD)–associated dysbiosis could predispose patients to relapse. Gut microbiota composition of from the prospective cohort study designed identify predictive factors clinical relapse after infliximab discontinuation (STORI Study) was investigated determine impact in CD Fecal samples 33 with this were collected at baseline, 2 months, 6 and end follow-up period (19 relapsers 14 nonrelapsers). Healthy volunteers subjects (n = 29) used as a control group. The fecal assessed using...
Objective control of intestinal inflammation during inflammatory bowel disease (IBD) is becoming the main driver for medical treatment. However, monitoring tools-related burden remains poorly investigated. We aimed to evaluate their comparative acceptability and utility according patients with IBD.After a preliminary phase, final questionnaire encompassing self-administered physician questionnaires was prospectively consecutively submitted 916 IBD from 20 public private centers....
The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) prior inadequate response and/or intolerance corticosteroids, immunosuppressants, advanced therapy.
Abstract Background The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease. Miri demonstrated statistically significant improvements co-primary all key secondary endpoints versus (vs) PBO1. Here we present results on comparisons miri ustekinumab (uste), p40 directed anti-IL-12/IL-23 inhibitor from Phase 3,...
Abstract Background Up to 30% of patients with acute severe ulcerative colitis (ASUC) require urgent colectomy despite IV corticosteroids and rescue therapies infliximab or cyclosporin. JAK-inhibitors, like tofacitinib, have emerged as effective treatments for ASUC, but data on postoperative complications are limited.1, 2 Methods We conducted a multicenter, retrospective, case-control (1:2) study hospitalized ASUC who underwent colectomy, comparing treated tofacitinib (cases) prior their...
OBJECTIVES: The objective of this study was to evaluate short- and long-term outcomes infliximab in ulcerative colitis (UC), including optimization, colectomy, hospitalization. METHODS: This a retrospective multicenter study. All adult patients who received at least one infusion for UC were included. Cumulative probabilities event-free survival estimated by the Kaplan–Meier method. Independent predictors identified using binary logistic regression or Cox proportional-hazards regression,...
To assess the characteristics and clinical course of nodular regenerative hyperplasia (NRH) in patients with inflammatory bowel disease treated azathioprine, so as to estimate frequency this complication search for risk factors.Cases were identified through a systematic survey followed at 11 centres. At one centre, cumulative NRH was estimated case-control study undertaken identify factors.37 cases (30 male, 7 female) between 1994 2005. The median dose azathioprine 2 mg/kg/d (range 1.5 3.0)....